How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,770 results for

Thromboembolic Disease in Pregnancy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

3701. Phase 1 Study OF CDC-501 in Patients With Solid Tumors

Summary: To identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment. Condition or disease Intervention/treatment Phase Neoplasms Drug: Lenalidomide Phase 1 Detailed Description: Identify the maximum tolerated dose (MTD) and safety of CDC-501 when given in a 6-week cycle in patients with solid tumors that are refractory after standard treatment Study Design Go to Layout table for study (...) to the study visit schedule and other protocol requirements. Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days prior to baseline. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner). Exclusion Criteria Myocardial infarction within the previous 6 months, unstable

2002 Clinical Trials

3702. Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

or past history of thromboembolic disorders, or cerebral vascular disease Gall bladder disease or liver dysfunction or disease, including hepatic adenomas or carcinoma, or abnormal liver function tests Known hypersensitivity to depoMPA contraceptive injection (medroxyprogesterone acetate or any of its other ingredients) Depression that is currently not under control, in the judgement of the Principal Investigator History of epilepsy History of diabetes Coronary artery disease Age >=35 and a current (...) risk for hereditary nonpolyposis colon cancer. It is not yet known which hormone therapy regimen is more effective in preventing endometrial cancer. Condition or disease Intervention/treatment Phase Endometrial Cancer Drug: medroxyprogesterone Drug: ethinyl estradiol Drug: norgestrel Other: laboratory biomarker analysis Phase 2 Detailed Description: PRIMARY OBJECTIVES: I. The primary objective is to evaluate the effect of progesterone therapy versus combination estrogen and progesterone therapy

2002 Clinical Trials

3703. Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

or metastatic pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of gemcitabine with or without dalteparin in treating patients who have unresectable or metastatic pancreatic cancer. Condition or disease Intervention/treatment Phase Pancreatic Cancer Thromboembolism Drug: dalteparin Drug: gemcitabine hydrochloride Procedure: quality-of-life assessment Phase 3 Detailed Description: OBJECTIVES: Compare the quality of life of patients with unresectable or metastatic pancreatic (...) cancer treated with gemcitabine with or without dalteparin. Compare the survival of patients treated with these regimens. Compare the incidence of venous thromboembolic complications in patients treated with these regimens. Determine the safety of dalteparin, in terms of bleeding complications, in these patients. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to disease stage (unresectable nonmetastatic vs metastatic). Patients are randomized to one of two

2002 Clinical Trials

3704. Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer

metastases No significant ascites, pleural effusions, or edema that would inhibit oral food intake or invalidate weight determinations PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-2 Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: No uncontrolled hypertension No active thromboembolic disease No myocardial infarction within the past 3 months No prior congestive heart failure or thromboembolic events Pulmonary (...) cancer. Condition or disease Intervention/treatment Phase Anorexia Cachexia Lung Cancer Drug: megestrol acetate Radiation: radiation therapy Phase 3 Detailed Description: OBJECTIVES: Determine the effect of megestrol on weight in patients receiving radiotherapy for lung cancer. Determine the quality of life of patients treated with this drug. OUTLINE: This is a randomized, placebo-controlled, double-blind, multicenter study. Patients are stratified according to histology (non-small cell lung cancer

2002 Clinical Trials

3705. Haemorheological consequences of oestrogen and progestogen therapy. (PubMed)

or in combination, were found to cause a rise in blood viscosity. Oestrogens did so by raising haematocrit and plasma fibrinogen, parameters that are similarly raised in other conditions such as pregnancy and following surgery when venous thromboembolism is common. The synthetic progestogen, on the other hand, raised the blood viscosity by increasing the haematocrit and decreasing erythrocyte deformability, parameters that are similarly altered in occlusive arterial disease. The combined preparation raised

1989 European journal of obstetrics, gynecology, and reproductive biology

3706. Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

participation Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception for at least 2 weeks before and during study participation PRIOR CONCURRENT THERAPY: Biologic therapy: See Chemotherapy Prior nonmyeloablative transplantation allowed provided the following are true: Patient is not receiving concurrent immunosuppressive therapy Patient has no signs of graft-versus-host disease Concurrent epoetin alfa allowed if started at least 4 weeks prior to study entry (...) by stopping blood flow to the tumor. It is not yet known whether bevacizumab works better with or without thalidomide for multiple myeloma. PURPOSE: This randomized phase II trial is to see if bevacizumab works better with or without thalidomide in treating patients who have relapsed or refractory multiple myeloma. Condition or disease Intervention/treatment Phase Multiple Myeloma and Plasma Cell Neoplasm Biological: bevacizumab Drug: thalidomide Phase 2 Detailed Description: OBJECTIVES: Compare

2001 Clinical Trials

3707. A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma

contraceptives during the period of treatment. No patients with uncorrected hypothyroidism. No patients with insulin-dependent diabetes mellitus or fasting blood glucose >e; 150 mg/dL. No patients with HIV infection. No patients with a history of thromboembolic events who require prophylaxis for thromboembolic events with anticoagulants once entry into Cohort III has begun. Patients with a history of symptomatic gallbladder disease must have had a cholecystectomy. Contacts and Locations Go to Information (...) evaluation up to three times, one time on weeks 2, 8, 16, 28, 40, 52, and one month post last dose of SMS 201-955 pa LAR. The four cohorts for this study will receive 60 or 90 mg SMS 201-955 pa LAR injectable every four weeks for up to 52 weeks. Two of the cohorts will receive 10 mg Tamoxifen on a daily basis. Condition or disease Intervention/treatment Phase Neoplasm Metastasis Osteosarcoma Drug: OncoLAR® (Registered Trademark) Drug: tamoxifen Phase 1 Detailed Description: Osteosarcoma is the most

1999 Clinical Trials

3708. Motor Recovery in Recent Stroke Patients Treated With Amphetamine and Physical Therapy

for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: 980115 98-N-0115 First Posted: November 4, 1999 Last Update Posted: March 4, 2008 Last Verified: June 2004 Keywords provided by National Institutes of Health Clinical Center (CC): Rehabilitation Plasticity Stroke Amphetamine Motor Hemiparetic Thromboembolic Non-Hemorrhagic Infarction Additional relevant MeSH terms: Layout table for MeSH terms Stroke Paralysis Cerebrovascular Disorders Brain Diseases Central Nervous System (...) ), electroencephalographs, and transcranial magnetic stimulation (TMS) to evaluate patients. Patients participating in the study will be placed in one of two groups; Patients receiving dextroamphetamine and routine Rehabilitation Medicine Patients receiving a placebo "sugar pill" and routine Rehabilitation Medicine Patients that have improved motor recovery will undergo neuroimaging and neurophysiological studies to identify areas of the brain involved. Condition or disease Intervention/treatment Phase Cerebrovascular

1999 Clinical Trials

3709. Use of oral contraceptives by adolescents and its consequences in Finland 1981-91. (PubMed)

and from 25/1000 to 19.2/1000 in 18 year olds; fertility rates had fallen from 4.5/1000 to 2.3/1000 and from 23.5/1000 to 15.3/1000 respectively. Rates in 14 year olds fell only slightly. Gonorrhoea infection fell and HIV infection remained rare. Rates of hospital discharge after thromboembolic venous disease rose slightly.The increased use of oral contraceptives is the most likely explanation for decreasing abortion and fertility rates among teenagers. Increased reliance on the condom because (...) Use of oral contraceptives by adolescents and its consequences in Finland 1981-91. To study use of oral contraceptives among Finnish teenagers during 1981-91 and how abortions, childbirths, sexually transmitted diseases, and cardiovascular diseases changed during this period.Biannual cross sectional surveys with mailed questionnaires from 1981 onwards and analysis of national statistics.Finland.A nationwide sample of 14, 16, and 18 year olds. Sample size varied from 1249 to 3887 and response

Full Text available with Trip Pro

1992 BMJ : British Medical Journal

3710. Hypertension in Pregnancy

renal disease or diabetes • sBP >140 mmHg or dBP >90 mmHg n Recommended treatment of non-severe hypertension in pregnancy • Treatment goal: dBP 80-105 mmHg (depending on practitioner preference) o First choice agent: Methyldopa (Aldomet) o second choice agents: Labetalol (Trandate); Nifedipine (Adalat PA or XL) o special indications (renal or cardiac diseases): diuretics • Drugs to avoid: angiotensin-converting enzyme inhibitors; angiotensin II receptor antagonists; atenolol n Acute management (...) of pregnancies than in the non-hypertensive cohort. By instituting the standardized protocol proposed within this guideline for the assessment, surveillance, and management of all women admitted to a BC healthcare facility with a HDP, the TESS project is anticipated to improve maternal and neonatal outcomes in BC. 3. ri Sk FA c Tor S • Family history • extremes of reproductive age • Primigravida • Multiple gestation • Diabetes, renal disease, hypertension prior to pregnancy • Collagen vascular disease

2006 British Columbia Perinatal Health Program

3711. BAES Guidelines on Training and Management of Endocrine Disease

BAES Guidelines on Training and Management of Endocrine Disease GUIDELINES FOR THE SURGICAL MANAGEMENT OF ENDOCRINE DISEASE AND TRAINING REQUIREMENTS FOR ENDOCRINE SURGERY THE BRITISH ASSOCIATION OF ENDOCRINE SURGEONS2 Guidelines for the Surgical Management of Endocrine Disease CONTENTS 1 GUIDELINES 3 2 SURGICAL TREATMENT OF DISEASES OF THE THYROID GLAND 2.1 MANAGEMENT OF PATIENTS WITH NODULAR GOITRE 4 2.2 THYROID MALIGNANCY 5 Follicular Cancer 6 Medullary Thyroid Cancer (MTC) 7 Thyroid (...) Lymphoma 8 2.3 ANAPLASTIC THYROID CANCER 8 2.4 THYROTOXICOSIS 9 3 SURGICAL TREATMENT OF THE PARATHYROID GLANDS 3.1 PRIMARY HYPERPARATHYROIDISM 10 3.2 RENAL HYPERPARATHYROIDISIM (Secondary or Tertiary Hyperparathyroidism) 11 4 SURGICAL TREATMENT OF DISEASES OF THE ADRENAL GLAND Investigations 12 Cushings Syndrome 12 Primary Hyperaldosteronism - Adrenocortical Adenoma- Conn’s Syndrome 12 Phaeochromocytoma 12 Incidentaloma 12 Adrenocortical Carcinoma 13 5 SURGICAL TREATMENT OF THE ENDOCRINE PANCREAS 5.1

2003 British Association of Endocrine and Thyroid Surgeons

3712. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA study

or surgery on the central nervous system, eyes or ears in the last 2 months, intravascular coagulation attributable to HIT, acute or subacute endocarditis, follow-up not possible, pregnancy, end-stage disease or life expectancy of less than 3 months, and participation in another study in the previous month. Setting The setting was secondary care and community care. The economic study was carried out in Spain. Dates to which data relate The effectiveness and resource use data were from 2002 to 2005 (...) Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA study Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA study Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice

2006 NHS Economic Evaluation Database.

3713. Are patients with peripheral vascular disease at increased risk of MI or DVT during long-haul flights, if so what is the increased risk?

risk? We searched the TRIP and Medline databases but found no guidelines or studies discussing or reporting on the risk of suffering a myocardial infarction or deep vein thrombosis in patients with peripheral vascular disease (or peripheral arterial disease) on long-haul flights. A general search of the Internet led us to a report by the WHO on global hazards of travel, published this year, and this discusses the risk of developing travel-related venous thromboembolism. The WHO report describes (...) Are patients with peripheral vascular disease at increased risk of MI or DVT during long-haul flights, if so what is the increased risk? Are patients with peripheral vascular disease at increased risk of MI or DVT during long-haul flights, if so what is the increased risk? - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere

2007 TRIP Answers

3714. Ximelagatran reduced venous thromboembolism more than warfarin after total knee replacement

Ximelagatran reduced venous thromboembolism more than warfarin after total knee replacement Ximelagatran reduced venous thromboembolism more than warfarin after total knee replacement | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ximelagatran reduced venous thromboembolism more than warfarin after total knee replacement Article Text Therapeutics Ximelagatran reduced venous thromboembolism more than warfarin after total knee replacement Free

Full Text available with Trip Pro

2005 Evidence-Based Medicine (Requires free registration)

3715. Ximelagatran prevented secondary venous thromboembolism

<90 000/mm 3 , pregnancy, lactation, expected survival <18 months, renal impairment, clinically important liver disease, or persistent elevation of the aminotransferase level >3 times the upper limit of normal. Intervention: twice daily ximelagatran, 24 mg (n = 612), or placebo (n = 611) for 18 months. All patients discontinued anticoagulant therapy but did not begin study treatment until the international normalised ratio (INR) was <1.5. Outcomes: VTE (recurrent DVT and PE), major and minor (...) Ximelagatran prevented secondary venous thromboembolism Ximelagatran prevented secondary venous thromboembolism | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name

Full Text available with Trip Pro

2005 Evidence-Based Medicine (Requires free registration)

3716. Tamoxifen reduced breast cancer risk but increased risks of thromboembolic events and all cause mortality in women

to receive tamoxifen, 20 mg/day (n=3578), or matching placebo (n=3574) for 5 years. Main outcome measures Breast cancer, endometrial cancer, thromboembolic events, cardiovascular events, and mortality. Main results Analysis was by intention to treat. Tamoxifen reduced the risk of breast cancer more than did placebo (table); age (<50 or ≥50 y), hormone replacement therapy use (during or before the trial, or never), and definition of invasiveness (ductal carcinoma in situ or invasive disease) did (...) Tamoxifen reduced breast cancer risk but increased risks of thromboembolic events and all cause mortality in women Tamoxifen reduced breast cancer risk but increased risks of thromboembolic events and all cause mortality in women | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username

Full Text available with Trip Pro

2004 Evidence-Based Medicine (Requires free registration)

3717. BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease

with antitrypanosomal agents or an accepted indication for antiparasitic therapy Inability to comply with follow-up visits History of severe alcohol abuse within 2 years Known chronic renal or hepatic insufficiency or hepatic insufficiency Pregnancy or breast feeding Megaesophagus with swallowing impairment Other severe disease significantly curtailing life expectancy Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact (...) BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2005 Clinical Trials

3718. Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis

Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00123149 Recruitment Status : Withdrawn First Posted : July 22

2005 Clinical Trials

3719. Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease

infections with fever Significant hirsutism (Ferriman Gallwey score≥8) Congenital adrenal hyperplasia Late onset congenital adrenal hyperplasia Systemic corticosteroid use (including previous use) Topical corticosteroid use Menstrual irregularity History of thromboembolism Uncontrolled diabetes or hypertension History of psychosis Pregnancy Lactation History of hypersensitivity to tetracosactin Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study (...) Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Adrenal Functions

2007 Clinical Trials

3720. Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease

infection and/or intestinal infection requiring antibiotic therapy at time of screening or baseline Evidence of chronic hepatitis B or C viral infection Decompensated liver disease Clinically significant ECG abnormalities History of angina or cardiac arrhythmia requiring drug or device intervention or clinically significant congestive heart failure or other clinically significant cardiac disease History of myocardial infarction within 12 months of screening History of thromboembolic disease (e.g (...) Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety

2003 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>